ONL Therapeutics, a retinal diseases therapy developer spun out of University of Michigan, closed a $4.25m series A round on Wednesday that featured the institution’s Michigan Investment in New Technology Startups (Mints) program.

Invest Michigan, a non-profit funded by state-owned investment vehicle Michigan Strategic Fund, also participated, as did pharmaceutical firm Novartis, Capital Community Angels, Biosciences Research & Commercialization Center and Hestia Investments.

The series A round included the conversion of a $1m bridge loan and was announced concurrently with…